Author Archives for Adeline Chauvigné

Healthcare sovereignty is closely linked to industrial recovery!

5 July 2025

The key issue of the Plan France 2030 centres on restoring French sovereignty in certain strategic areas in order to... View Article

Valneva wins approval from European Commission to supply Covid-19 vaccines

5 July 2025

Valneva, a specialty vaccine company and member of Atlanpole Biotherapies, announced that the European Commission (“EC”) has approved an agreement... View Article

New member | AGS-M

5 July 2025

AGS-M is a young CDMO dedicated to the development, the optimization and validation of manufacturing processes (production, clarification, purification and... View Article

Valneva raises €88 million

5 July 2025

Valneva, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new... View Article

Innovative medical device same™ by i-SEP : promising clinical results

5 July 2025

MedTech – Autotransfusion or IntraOperative Cell Recovery Recovery of platelets in addition to red blood cells, a world premiere Following... View Article

KetoM+ is launching Cétoprane, a ketogenic medical food (DADFMS)

5 July 2025

KetoM+, member of our network based in Le Mans, is launching Cétoprane, a ketogenic medical food (DADFMS) nutritionally adapted for... View Article

New member | Elisabeth Richard Business Development Consulting

5 July 2025

Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

5 July 2025

VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article

Owkin joins OPTIMA: new research project to improve the treatment of prostate, breast and lung cancer patients using AI

5 July 2025

Owkin is delighted to be part of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence),... View Article

Hawkcell & Cynbiose team up in a strategic partnership

5 July 2025

Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and... View Article